EICHORPublic-registry site landscape for NCT07708727, “Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment”, a HIV-1-infection study sponsored by Gilead Sciences. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07708727 (registry record) |
| Study title | Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment |
| Official title | An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1 |
| Sponsor | Gilead Sciences |
| Condition(s) | HIV-1-infection |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 0 |
| Intervention(s) | GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF |
Patient-friendly overview of this study: eichor.com/study/NCT07708727.
Eichor generates a preliminary site-risk snapshot for NCT07708727 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
